Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
157 Leser
Artikel bewerten:
(0)

OHK Medical Devices Selects Henry Schein as Exclusive Distributor of HemaClear / New innovative surgical tourniquet device quickly and effectively creates a bloodless field for limb surgery

NEWARK, N.J., Feb. 16, 2011 /PRNewswire/ -- OHK Medical Devices, Inc. announced today that it has selected Henry Schein Medical, the U.S. physician business of Henry Schein Inc. , the largest distributor of health care products and services to office-based dental, medical and veterinary practitioners, as the exclusive distributor of HemaClear® for the U.S. alternate care market. HemaClear is the first and only surgical tourniquet single-use device that exsanguinates, occludes, and provides a clearer surgical field.

"HemaClear is delighted to be partnering with a company that has such an excellent reputation for bringing its customers the highest quality and most innovative products on the market," said Oren Gavriely, Chief Executive Officer, OHK Medical Devices. "We are very much looking forward to bringing this new, revolutionary standard of care to Henry Schein customers around the country."

An exsanguination device that prepares any limb for surgery in less than 12 seconds, HemaClear provides a larger, dryer, and clearer surgical field, thereby providing the surgeon with a better view of anatomical structures. Its ease of use and simplicity saves valuable operating room time. HemaClear has been proven worldwide in over 180,000 surgical cases.

"Henry Schein Medical is pleased to exclusively offer HemaClear as part of our ongoing commitment to help drive the success of our customers' practices and enable them to provide the highest quality care," said Dave McKinley, President of Henry Schein Medical. "This innovative new technology is simple, sterile, safe, cost-effective, and ultimately provides more successful surgical outcomes, especially for our customers that practice in ambulatory surgical settings and perform office-based procedures."

About HemaClear

Manufactured by OHK Medical Devices, Inc., headquartered in Haifa, Israel, HemaClear® is the first self-contained, sterile, exsanguinating tourniquet that creates a bloodless field in seconds. HemaClear® performs three functions: blood removal (exsanguination), arterial flow occlusion, and automatic application of the sterile stockinet. HemaClear® replaces traditional devices, completely eliminating the need for a tourniquet machine, tourniquet cuff, Esmarch bandage, Webril(TM) and stockinet.

Perhaps most advantageous of all, from a logistics point of view, HemaClear® is self-contained and requires absolutely no connections or power source. HemaClear's innovative technology not only reduces blood loss, infection, and the volume of ischemic tissue, its simplicity saves precious operating room set-up time' as much as fifteen minutes' and over 10 separate steps and products that can save as much as $300 a procedure.

Hemaclear is used as a standard of care in over 25 countries and over 180,000 of Hemaclear's tourniquets have been applied. For more information, visit the HemaClear site at http://www.hemaclear.com/, or visit http://www.youtube.com/watch?v=L46SI03Lpl0

About Henry Schein

Henry Schein, Inc. , the largest provider of health care products and services to office-based practitioners, is a Fortune 500® company and a member of the NASDAQ 100® Index. The Company is recognized for its excellent customer service and highly competitive prices. Henry Schein's five businesses - North American Dental, North American Medical, North American Animal Health, International and Technology - serve more than 700,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.

Headquartered in Melville, N.Y., Henry Schein employs more than 14,000 people and has operations or affiliates in 24 countries. The Company's net sales reached a record $6.5 billion in 2009. For more information, visit the Henry Schein Web site at http://www.henryschein.com/.

OHK Medical Devices, Inc.

CONTACT: OHK Medical Devices Inc., T: 1-866-841-0221, F: 1-866-430-6132,
info@hemaclear.com

Company News On-Call: http://www.prnewswire.com/comp/124741.html

© 2011 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.